No abstract

Living donor liver transplantation (LDLT) is an accepted option for end-stage liver disease, particularly in countries in which there are organ shortages. However, little is known about LDLT for obese patients. We sought to determine the effects of obesity on pretransplant living donor selection for obese recipients and their outcomes. On the basis of body mass index (BMI) values, 148 patients were classified as normal weight (N), 148 were classified as overweight (OW), and 74 were classified as obese (O). O recipients had significantly greater BMI values (32.1 6 1.6 versus 23.2 6 1.9 kg/m 2 , P < 0.001) and received larger actual grafts (918.9 6 173 versus 839.4 6 162 g, P 5 0.002) than recipients with normal BMI values. Donors who donated to O recipients had a greater mean BMI (26.3 6 3.8 kg/m 2 ) than those who donated to N recipients (24.4 6 3.2 kg/m 2 , P 5 0.001). Although O recipients were more likely to face some challenges in finding a suitable living donor, there were no differences in graft survival [hazard ratio (HR) 5 0.955, 95% confidence interval (CI) 5 0.474-1.924, P 5 0.90] or recipient survival (HR 5 0.90, 95% CI 5 0.56-1.5, P 5 0.67) between the 3 groups according to an adjusted Cox proportional hazards model. There were no significant differences in posttransplant complication rates between the 3 recipient groups or in the morbidity rates for the donors who donated to O recipients versus the donors who donated to OW and N recipients (P 5 0.26). Therefore, we recommend that obese patients undergo pretransplant evaluations. If they are adequately evaluated and selected, they should be considered for LDLT. Liver Transpl 20:311-322, 2014. V C 2013 AASLD.

Limberg transposition flap may be use in recurrent cases of PSD, because of the lower recurrence rate and less hospital stay time, early return to work. Most important advantage of fasciocutaneous V-Y advancement flap is the ability to close larger defects in recurrent cases.

No abstract

The predicting factors of NSLNM were LVI, ECI, Ki-67 level, Her-2 reseptor positive and but should be further validated in our institutions, different institutions and different patient groups prospectively.